1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow AMG 745: new trials by email Literature Review of AMG 745 trials Research Report on AMG 745
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMG 745 in Subjects With Age-associated Muscle Loss AMG 745 0.3 mg/kg, AMG 745 1.0 mg/kg, AMG 745 3.0 mg/kg - Age-associated Muscle Loss | Phase 2 | Withdrawn | Amgen | 2010-04-01 | 2018-10-04 |
Atrophy (1) · Frailty (1) · Motor Activity (1) · Muscular Atrophy (1) · Sedentary Behavior (1)
Amgen (1)